Monika Kandebo

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index457citations17works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phosphodiesterase function and regulation(8), Cholinesterase and Neurodegenerative Diseases(6), Lysosomal Storage Disorders Research(5), Parkinson's Disease Mechanisms and Treatments(4), Cellular transport and secretion(4)

Publications17 total

Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia
Journal of Pharmacology and Experimental Therapeutics·2024· 3 citedOpen Access
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson’s Disease
ACS Medicinal Chemistry Letters·2023· 11 citedOpen Access
Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia
Journal of Medicinal Chemistry·2023· 37 citedOpen Access
Pharmacological profile of MK-8189, a novel phosphodiesterase 10A inhibitor, and relationship between phosphodiesterase 10A enzyme occupancy and preclinical efficacy
Neuroscience Applied·2023Open Access
Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions
Journal of Neuroscience·2022· 35 citedOpen Access
P546. Preclinical Characterization and Phase 1 Evaluation of the Tolerability, Pharmacokinetics, and Enzyme Occupancy of MK-8189, a Novel PDE10A Inhibitor
Biological Psychiatry·2022· 2 cited
Validation of a multiplexed and targeted lipidomics assay for accurate quantification of lipidomes
Journal of Lipid Research·2022· 18 citedOpen Access
Neuronopathic GBA1 L444P mutation accelerates Glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions
2022· 2 citedOpen Access
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy
Neurobiology of Disease·2021· 20 citedOpen Access
Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model
PLoS ONE·2021· 40 citedOpen Access
Synthesis and optimization of N-heterocyclic pyridinones as catechol-O-methyltransferase (COMT) inhibitors
Bioorganic & Medicinal Chemistry Letters·2016· 10 citedOpen Access
Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia
Bioorganic & Medicinal Chemistry Letters·2015· 26 citedOpen Access
The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents
Neuropharmacology·2015· 20 cited
Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia
Bioorganic & Medicinal Chemistry Letters·2012· 34 citedOpen Access
The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey
Neuropharmacology·2012· 84 citedOpen Access
Characterization of Non-Nitrocatechol Pan and Isoform Specific Catechol-<i>O</i>-methyltransferase Inhibitors and Substrates
ACS Chemical Neuroscience·2011· 34 cited
The Behavioral and Neurochemical Effects of a Novel d-Amino Acid Oxidase Inhibitor Compound 8 [4 H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and d-Serine
Journal of Pharmacology and Experimental Therapeutics·2008· 81 cited

Frequent Co-authors

Sean M. Smith(16), Jason M. Uslaner(9), Lihang Yao(8), Christopher D. Cox(7), Izzat T. Raheem(7), Sarah L. Huszar(5), Nathan G. Hatcher(5), Jacob Marcus(5), Dawn Toolan(4), Paul J. Coleman(4), John J. Renger(4), Liza Gantert(4), Eric D. Hostetler(4), Joshua D. Vardigan(3), John D. Schreier(3), Nancy A. Sachs(3), Mali Cosden(3), Robert E. Drolet(3), M. E. Layton(3), Bennett Ma(3)